Some large-scale cohort studies in Western countries, and in eastern Asian and Asia-Pacific countries have shown weak as well as positive associations between total cholesterol and mortality from cerebral infarction. 14- 18 Nevertheless, cohort studies conducted in Japan have failed to demonstrate a positive association. 10,19-21 Serum total cholesterol levels have been negatively associated with cerebral hemorrhage. 14,17,21- 25 The association between non-HDL cholesterol and risk of stroke has not been analyzed completely.
Japan Arteriosclerosis Longitudinal Study -Existing Cohorts Combine (JALS-ECC) is a project pooling the data of 21 cohort studies in Japan. 26 Fifteen cohorts have recorded the incidence of acute myocardial infarction (AMI) and 18 cohorts have recorded stroke subtypes as endpoints. The purpose of the present study was to use this database to clarify whether serum non-HDL cholesterol levels can predict these cardiovascular events more reliably than serum total cholesterol levels in the Japanese general population. An additional purpose was to construct scoring systems to predict 5-year probabilities of these cardiovascular events by using serum total or non-HDL cholesterol levels along with other risk factors.
Methods
Study design and methods of the JALS-ECC have been described elsewhere. 26 Anonymously provided individual records for 66,691 participants in 21 cohort studies were included in this project. Permission to submit each collection of cohort data to the JALS central office was obtained from the respective institute review boards for ethics issues. Ten cohorts were selected for the present analysis (Table 1) using the following criteria: (1) endpoints included the incidence of AMI or stroke subtypes; and (2) baseline data included serum total cholesterol, serum HDL cholesterol, blood pressure, height, weight, smoking status, and history of diabetes. The Tokamachi cohort was included only for the AMI analysis because it lacked data on stroke events. In total, for the analysis for AMI, we enrolled 22,430 subjects (aged 40-89) who were free from ischemic heart disease and stroke from 10 cohorts, and for the analysis for stroke, we enrolled 15,269 subjects from 9 cohorts. The total follow-up period was 160,887 person-years for AMI and 102,984 person-years for stroke.
Risk Factors
Serum levels of total and HDL cholesterol had been measured at baseline. For each individual, non-HDL cholesterol level was determined by subtracting serum level of HDL cholesterol from that of total cholesterol. All subjects were stratified into quartile categories based on their total and non-HDL cholesterol levels: ≤175 mg/dl, 176-198 mg/dl, 199-223 mg/dl, and ≥224 mg/dl for total cholesterol and ≤117 mg/dl, 118-141 mg/dl, 142-166 mg/dl, and ≥167 mg/dl for non-HDL cholesterol ( Table 2 ). The median of each quartile was 160 mg/dl, 188 mg/dl, 210 mg/dl, and 243 mg/dl for total cholesterol and 103 mg/dl, 130 mg/dl, 154 mg/dl, and 187 mg/dl for non-HDL cholesterol.
Blood pressure was measured using a standard sphygmomanometer in all cohorts and categorized according to the 1999 criteria of the World Health Organization and International Society of Hypertension: 27 high -normal or less; grade 1 hypertension; grade 2 hypertension; and grade 3 hypertension. Body mass index was calculated based on height and weight data measured at baseline. Current smoking status and history of diabetes were assessed based on the declaration of the study subjects. Values are mean ± SD or n (%). JALS, Japan Arteriosclerosis Longitudinal Study; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; AMI, acute myocardial infarction; TS, total stroke; CInf, cerebral infarction; CH, cerebral hemorrhage; SAH, subarachnoid hemorrhage.
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Endpoint Determination
In each cohort, cardiovascular event development was ascertained during follow up by population-based stroke and/or MI registration systems on the basis of data from death certificates, medical records in hospitals and/or questionnaires. The diagnosis of stroke was based on typical clinical features and characteristic changes on computed tomography and/or magnetic resonance imaging brain scans, while the diagnosis of MI was based on chest pain, cardiac enzyme levels, and electrocardiograms. These criteria were based on criteria from the MONICA study 28 or from the World Health Organization. 29, 30 In total, 104 events of AMI, 339 events of total stroke (224 events of cerebral infarction, 65 events of cerebral hemorrhage, 48 events of subarachnoid hemorrhage and 2 stroke events of unknown subtype) had been recorded as cardiovascular events. The annual incidence per 1,000 person-years was 0.65 for AMI and 3.29 for total stroke (2.17 for cerebral infarction, 0.63 for cerebral hemorrhage and 0.46 for subarachnoid hemorrhage).
Statistical Analysis
Poisson regression was used to calculate the incidence rate ratios (IRR) and 95% confidence intervals (CI) for cardiovascular events according to quartiles of serum total or non-HDL cholesterol levels. A trend test was applied to examine the dose-dependent relationship between quartile levels of serum total or non-HDL cholesterol and the risk of cardiovascular events; the categorical data were treated as continuous using the median value of total or non-HDL cholesterol level in each quartile category, and the statistical significance was tested using the log-likelihood chi-square statistic. IRRs per 1SD increment were also calculated by using actual values of total or non-HDL cholesterol levels (continuous model). Ageand sex-adjusted IRRs were calculated in analyses for both sexes; age-adjusted IRRs were calculated separately for men and women. Age was categorized in 10-year intervals. Sexspecific analysis was not used for hemorrhagic stroke events due to low incidence. The multivariable adjusted model further adjusted for body mass index (<20 kg/m 2 , ≥20 -<25 kg/m 2 , ≥25 kg/m 2 ), serum HDL cholesterol level (<40 mg/dl, ≥40 mg/dl), blood pressure (<high -normal, grade 1, grade 2, grade 3), diabetes (present/absent in the history) and current smoking status. The body mass index, serum HDL cholesterol level, and blood pressure were classified on the basis of currently available criteria. 27,31,32 Furthermore, we constructed scoring systems to estimate the 5-year probability of developing cardiovascular events based on multivariable Poisson regression models (scorerating models). In each model, serum total or non-HDL cholesterol level was entered as a continuous variable and the IRR for every 1-mg/dl increment was calculated. For each variable, a score 0 was given to the referent status and other scores were determined so that every 10-point increment in the score represented a 2-fold increment in the hazard as Sex-specific analyses were not applied because of low incidence. §
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The categorical data were treated as continuous by using the median value of TC levels in each quartile category, and P was calculated for the log-likelihood chi-square statistic. ¶
The actual values of TC levels were entered as continuous variables to calculate IRR per 1-SD increment. Multivariable-adjusted IRR adjusted for sex, age, body mass index, serum HDL-C, blood pressure, diabetes, and current smoking status.
IRR, incidence rate ratio; CI, confidence interval. Other abbreviations see in Table 1 .
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The categorical data were treated as continuous by using the median of non-HDL-C levels in each quartile category, and P was calculated for the log-likelihood chi-square statistic. ¶
The actual values of non-HDL-C levels were entered as continuous variables to calculate IRR per 1-SD increment. Multivariable-adjusted IRR adjusted for sex, age, body mass index, serum HDL-C, blood pressure, diabetes, and current smoking status. Abbreviations see in Tables 1,3 .
follows: log2(IRR)×10. An integral score was determined by rounding off each calculated value except for serum total and non-HDL cholesterol levels; for each cholesterol level, a score change (∆score) for every 1-mg/dl increment was determined up to the second decimal place. Each referent level of total and non-HDL cholesterol was set at 200 mg/dl and at 140 mg/dl, respectively, so that a score for a serum level can be calculated by (serum level -referent level) × (∆score for every 1-mg/dl increment) to the first decimal place. A total score was then calculated for each individual based on one's risk status and entered in a Poisson model as an only variable.
A 5-year probability (%) for a cardiovascular event of an individual can be calculated by {1-exp[-(5-year cumulative hazard for total score = 0) × (1.0718 Total score )]}×100; 1.0718 is the IRR per every 1-point increment in total score, which is determined by 2 0.1 . In order to compare the predictive potential for cardiovascular events between models, the area under the receiver operating curve (AUC) was calculated for selected models by treating the probability of developing AMI at month 60 for each subject and the actual status at this time point as the predictive value and gold standard, respectively. 33, 34 The data of lost-to-follow up censored sub- Original model, models used for men and women combined analyses in Tables 3,4 . Score-rating model, models for calculating scores that are determined by a formula log2(IRR) ×10 in order that every 10-interval increase in total score represents 2-fold increase in the incidence rate of AMI. Tables 1,3 .
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jects with maximum follow-up periods of <60 months were excluded from the AUC analyses. SAS for Windows, release 9.13 (SAS Institute, Cary, NC, USA) was used to perform all statistical analyses. P<0.05 was considered statistically significant in all analyses.
Results
High serum total cholesterol levels were significantly associated with an elevated risk of AMI ( Results for all variables in the multivariable models for AMI used in Tables 3,4 (men and women combined) are shown in Table 5 as original models accompanied with results from the score-rating models. For the score-rating model, grade 2 and 3 hypertensions were combined because no substantial difference in IRR was observed between them in the original models. Body mass index was excluded from the score-rating model due to a non-significant U-shape association with risk of AMI in the original models. The AUC in the case of the score-rating model was slightly greater for the non-HDL cholesterol model (0.825) than for the total cholesterol model (0.816). Using hazard ratios in the scorerating models, a score was given for each risk status of every variable so that a total score was to be calculated for each individual. The IRR per every 1-mg/dl increment each in serum total and non-HDL cholesterol level (1.011 and 1.013, respectively) were translated to +0.16 points and +0.19 points, respectively; giving a score for each serum level by the following formulas: (serum total cholesterol level -200 mg/dl) × 0.16 and (serum non-HDL cholesterol level -140 mg/dl) × 0.19. When the total score was used as the only variable in the Poisson regression analysis, no substantial changes in the AUCs (0.815 for total cholesterol model and 0.825 for non-HDL cholesterol model) were found in comparison with the Table 1 .
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score-rating models. The cumulative hazard at month 60 for total score =0 was determined at 0.000175 for the total cholesterol model and at 0.000163 for the non-HDL cholesterol model; the 5-year probability (%) of developing AMI was determined by [1-exp(-0.000175 × 1.0718 Total score )] × 100 for the total cholesterol model and [1-exp(-0.000163 × 1.0718 Total score )] ×100 for the non-HDL cholesterol model. Scoring systems and 5-year probabilities are summarized in Tables 6,7 , respectively.
Discussion
The present study showed that serum total and non-HDL cholesterol are significantly associated with risk of AMI but not of stroke events. Therefore, we were able to develop scoring systems to evaluate the 5-year probability for AMI only.
The stronger association of non-HDL cholesterol than total cholesterol with risk of AMI is in agreement with previous studies for CHD 9,11 and for cardiovascular disease. 12, 13 Although direct measurement of serum LDL cholesterol is now widely accepted in Japan, we do not have sufficient evidence from cohort studies to evaluate a probability of developing CHD using serum LDL cholesterol for the Japanese general population. Thus, the use of non-HDL cholesterol should be recommended to predict the probability of CHD for the Japanese general population and probably for other Asian populations until a more reliable tool using serum LDL cholesterol level can be developed.
The present cohort study is currently the largest cohort study providing a tool for predicting probabilities of the AMI incidence in the Japanese general population. Our scoring systems allow individuals to evaluate their own probability of developing AMI within 5 years. This may help them in choosing an approach to reduce the risk. For example, the total score for a 65-year-old (score = 24) man (score = 16) solely with high non-HDL cholesterol of 193 mg/dl (score = 10) for the non-HDL cholesterol model is 50, and the corresponding 5-year probability of AMI is 0.52%. If this man also had all other risk factors simultaneously, the highest total score would be 78 and the 5-year probability would rise to 3.6%. These probabilities might be reduced by 48% among mild -moderate hypercholesterolemic persons 35 by medical treatment with statins, giving a revised 5-year probability of 0.27% and 1.9%, respectively. Such information could be helpful for an individual in deciding whether or not to accept medication. We did not develop a scoring system separately for men and women because no significant interaction was found between cholesterol levels and sex for risk of AMI. In addition to the non-HDL cholesterol model, the total cholesterol model was also prepared because some physicians might need it in their daily practice.
Recently, another tool predicting AMI risk in the Japanese general population was published by the Jichi Medical School cohort study (JMS study). 36 The differences between the tool used in their study and that used in the present study are primarily based on the magnitude of the contributions of some factors to risk prediction; for example, the contributions of diabetes mellitus in women and smoking in both sexes were larger while that of diabetes mellitus in men was smaller in the JMS study than in the present one. Serum HDL cholesterol was not introduced in the JMS study tool. Therefore, the estimated absolute risk would be different between the two tools.
In the present study neither serum total nor non-HDL cholesterol was associated with risk of cerebral infarction, as IRR against score 0" being doubled along with every 10 increment in the score. Other abbreviations see in Table 1 .
indicated in previous studies of the Japanese general population. 10,19-21 Because serum total or LDL cholesterol is associated with atherothrombotic infarction but not with lacunar infarction, 37,38 the lack of the association between serum total cholesterol and cerebral infarction in Japanese populations could partly be explained by the high frequency of lacunar infarction. The Hisayama cohort study conducted in a Japanese rural community reported that lacunar infarction was 5 times more frequent than atherothrombotic infarction. 19 A hospital-based registry in an urban area (the city Osaka) reported this lacunar/atherothrombotic infarction ratio to be 2. In contrast, serum total cholesterol level has been inversely associated with the incidence of atrial fibrillation 49 and with the prevalence of paroxysmal atrial fibrillation. 50 It is likely that these inverse associations will counteract the positive association between serum total cholesterol levels and atherothrombotic cerebral infarction in Japanese and possibly other populations where atherothrombosis is not a predominant cause of cerebral infarction. Furthermore, a very low event rate of AMI in Japan, 51-54 and possibly the low frequency of cerebral embolism secondary to MI may limit the contribution of total, non-HDL, or LDL cholesterol as factors for predicting the risk of cerebral infarction. Unlike previous studies, 14,17,21-25 we did not observed a negative association between serum total or non-HDL cholesterol levels and the risk of cerebral hemorrhage in the present study, probably because of the relatively small number of incidences in the present study. Risk of subarachnoid hemorrhage was not associated with serum total or non-HDL cholesterol levels; nevertheless, further studies to evaluate this lack of association with more cases are warranted.
Because JALS-ECC is a pooling project of already existing cohorts, the present study has some limitations. Items surveyed at baseline varied by cohort, and we were unable to include some important information because of limited data in some cohorts; these included treating status of hypertension and hyperlipidemia, information to differentiate current smokers and ex-smokers, number of cigarettes smoked per day, and menopause status. As for diabetic status, only subjective history could be included in the analysis because information concerning treating status, plasma glucose and hemoglobin A1c were not available for all cohorts. It is highly likely that smoking and diabetic status were not significantly associated with the risk of AMI in the present study because the aforementioned criteria were not assessed. Despite the lack of statistical significance, we included smoking and diabetesestablished risk factors for CHD in Japanese people 55-57 -in the scoring systems for predicting AMI probability in order to avoid underestimating their effects. We also introduced some other statistically non-significant factors in the scoring systems. The age group of 50-59 years was introduced because there was a clear log-linear relationship between age categories and IRRs. We also considered that intermediately elevated risk of grade 1 hypertension could not be negligible in risk prediction because a linear association between blood pressure and CHD risk has been reported in Asia-Pacific populations. 58 The validity of our scoring systems will be evaluated in an ongoing larger cohort study 59 by comparing the estimated probability of AMI with its actual incidence.
Second, the diagnostic criteria of cardiovascular events were difficult to standardize strictly between studies, although no substantial differences in the definitions of major cardiovascular events were found between each cohort. 26 The JALS is now ongoing in order to resolve these limitations. 59 The JALS is a multicenter cohort study using standardized criteria in correcting baseline data and in enrolling endpoints. Therefore, more sophisticated tools for predicting the risk of cardiovascular events could be developed over the next several years.
It is likely that the 5-year probabilities of AMI were underestimated, but this limitation is inherent for cohort studies in general. As in the present cohort studies, relatively definite cases were generally enrolled as endpoints in order to estimate reliable relative risks of the associated risk factors. Therefore, some suspected cases of AMI as well as some non-diagnosed cases cannot be taken into account for this estimation. This limitation should always be considered when our scoring systems are used. Another limitation was that we were unable to consider serum LDL cholesterol measurements. Further large-scale studies are thus required to clarify whether serum LDL cholesterol is superior to serum non-HDL cholesterol for the prediction of cardiovascular events.
Although we have applied absolute values of total or non-HDL cholesterol levels for estimating the probabilities of AMI, total to HDL cholesterol ratio is also a strong predictor of CHD. 60 The non-HDL to HDL cholesterol ratio may provide some additional information for the prediction. The independencies of these cholesterol ratios from absolute values of cholesterol levels and their application in estimating the probabilities of AMI should also be discussed. Therefore, we will analyze and report the significance of the cholesterol ratios in the future.
In conclusion, compared to serum total cholesterol levels, serum non-HDL cholesterol levels were more strongly associated with the risk of AMI, in a dose-dependent manner. Our scoring systems can be useful tools to assess an individual's risk of developing AMI by measuring serum total cholesterol and HDL cholesterol levels for Japanese and probably Asian populations. Neither total nor non-HDL serum cholesterol levels can be used to estimate risk of stroke in the Japanese general population.
